GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sinovac Biotech Ltd (NAS:SVA) » Definitions » ROE %

Sinovac Biotech (Sinovac Biotech) ROE % : 0.38% (As of Jun. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Sinovac Biotech ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Sinovac Biotech's annualized net income for the quarter that ended in Jun. 2023 was $33.8 Mil. Sinovac Biotech's average Total Stockholders Equity over the quarter that ended in Jun. 2023 was $8,793.1 Mil. Therefore, Sinovac Biotech's annualized ROE % for the quarter that ended in Jun. 2023 was 0.38%.

The historical rank and industry rank for Sinovac Biotech's ROE % or its related term are showing as below:

SVA' s ROE % Range Over the Past 10 Years
Min: -3.92   Med: 8.41   Max: 168.11
Current: -3.92

During the past 13 years, Sinovac Biotech's highest ROE % was 168.11%. The lowest was -3.92%. And the median was 8.41%.

SVA's ROE % is not ranked
in the Biotechnology industry.
Industry Median: -44.355 vs SVA: -3.92

Sinovac Biotech ROE % Historical Data

The historical data trend for Sinovac Biotech's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinovac Biotech ROE % Chart

Sinovac Biotech Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.77 16.41 21.21 168.11 1.25

Sinovac Biotech Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 308.68 88.40 10.31 -8.06 0.38

Competitive Comparison of Sinovac Biotech's ROE %

For the Biotechnology subindustry, Sinovac Biotech's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sinovac Biotech's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sinovac Biotech's ROE % distribution charts can be found below:

* The bar in red indicates where Sinovac Biotech's ROE % falls into.



Sinovac Biotech ROE % Calculation

Sinovac Biotech's annualized ROE % for the fiscal year that ended in Dec. 2022 is calculated as

ROE %=Net Income (A: Dec. 2022 )/( (Total Stockholders Equity (A: Dec. 2021 )+Total Stockholders Equity (A: Dec. 2022 ))/ count )
=113.866/( (9327.435+8921.421)/ 2 )
=113.866/9124.428
=1.25 %

Sinovac Biotech's annualized ROE % for the quarter that ended in Jun. 2023 is calculated as

ROE %=Net Income (Q: Jun. 2023 )/( (Total Stockholders Equity (Q: Dec. 2022 )+Total Stockholders Equity (Q: Jun. 2023 ))/ count )
=33.836/( (8921.421+8664.871)/ 2 )
=33.836/8793.146
=0.38 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Jun. 2023) net income data. ROE % is displayed in the 30-year financial page.


Sinovac Biotech  (NAS:SVA) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Jun. 2023 )
=Net Income/Total Stockholders Equity
=33.836/8793.146
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(33.836 / 280.808)*(280.808 / 13919.789)*(13919.789 / 8793.146)
=Net Margin %*Asset Turnover*Equity Multiplier
=12.05 %*0.0202*1.583
=ROA %*Equity Multiplier
=0.24 %*1.583
=0.38 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Jun. 2023 )
=Net Income/Total Stockholders Equity
=33.836/8793.146
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (33.836 / -127.22) * (-127.22 / -860.958) * (-860.958 / 280.808) * (280.808 / 13919.789) * (13919.789 / 8793.146)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= -0.266 * 0.1478 * -306.6 % * 0.0202 * 1.583
=0.38 %

Note: The net income data used here is two times the semi-annual (Jun. 2023) net income data. The Revenue data used here is two times the semi-annual (Jun. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Sinovac Biotech ROE % Related Terms

Thank you for viewing the detailed overview of Sinovac Biotech's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sinovac Biotech (Sinovac Biotech) Business Description

Traded in Other Exchanges
N/A
Address
No.39, Shangdi Xi Road, Haidan District, Beijing, CHN, 100085
Sinovac Biotech Ltd is a biopharmaceutical company. The company focuses on the research, development, manufacturing, and commercialization of vaccines for infectious diseases. Its product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps, and canine rabies. The company also provides services for disease control and prevention, collaborating with the Chinese governments at the national, state, and local levels. It sells its vaccines in China, while also exploring growth opportunities in international markets.
Executives
Lily Wang director, 10 percent owner, officer: Chief Financial Officer 300 MURCHISON DR., MILLBRAE CA 94030
Ifg Investments Services Inc 10 percent owner PO BOX 822, CHARLESTOWN FEDERATION OF ST KITTS & NEVIS WEST INDIES P8 00000
Yin Weidong director, 10 percent owner, officer: President and CEO
Terry G Bowering director, 10 percent owner, officer: President, CEO 10 CEDAR MEADOW DRIVE REGINA A9 S4X 3J6

Sinovac Biotech (Sinovac Biotech) Headlines

From GuruFocus

SINOVAC COVID-19 Vaccine Is Conditionally Registered In South Africa

By Business Wire Business Wire 06-25-2022

SINOVAC Varicella Vaccine Prequalified by WHO

By Business Wire Business Wire 11-04-2022